Home > Journals > Minerva Surgery > Past Issues > Articles online first > Minerva Surgery 2022 Sep 09

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

Original Article   

Minerva Surgery 2022 Sep 09

DOI: 10.23736/S2724-5691.22.09544-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Role of associating liver partition and portal vein ligation for staged hepatectomy for advanced colorectal liver disease: indispensable or overstressed?

Janine BAUMGART 1, Fabian BARTSCH 1, Michael KLOTH 2, Roman KLÖCKNER 3, Hauke LANG 1

1 Department of General, Visceral and Transplantation Surgery, Universitätsmedizin Mainz, Mainz, Germany; 2 Department of Diagnostic and Interventional Radiology, Universitätsmedizin Mainz, Mainz, Germany; 3 Department of Pathology, Universitätsmedizin Mainz, Mainz, Germany


PDF


BACKGROUND: The aim of this study was to analyse the role of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver disease. Surgery offers the best long-term survival in patients with colorectal liver metastases (CRLM). To increase the rates of resectability, two-stage procedures (TSH) and ALPPS are established methods in cases of advanced colorectal liver disease to avoid post hepatectomy liver failure (PHLF). There is still a debate of the oncological utility and the surgical ranking of ALPPS in this clinical scenario. The aim of this analysis was to share our ALPPS data of the perioperative and oncological outcome in patients with CRLM and to compare them with regard to recommendations of published data.
METHODS: Ten patients (1.1%) out of 881 received a classical ALPPS procedure between January 2008 and November 2021 at our institution. The median volume increase was 76% (range 55-125%) in a median time interval of 7 days.
RESULTS: The completion rate was 100% and all resections were R0-situations (100%). No patient developed PHLF. The median overall survival (OS) was 36.7 months and the median recurrence-free survival (RFS) 6.1 months.
CONCLUSIONS: The ALPPS procedure is a surgical approach to achieve a R0 situation in patients with an extensive intrahepatic tumor burden. Nevertheless, the use of ALPPS should be allocated for patients who have no other surgical options.


KEY WORDS: Neoplasm metastasis; Liver surgery; Hepatectomy

top of page